<!DOCTYPE html>
<html>
<head>
<style>
.rectangle1{
  width: 100%;
  height: 100px;
  background: #DADBDD;
  text-align: center;



}

body {
           text-align: center;
           /*background-image: url('img_girl.jpeg');*/
       }
.tableth{
  text-align:center;
  background-color:#FF6600;
  padding: 4px 30px 4px 8px;
  font-size:23px;
}
.tabletd{
  border: 1px solid #e3e3e3;
  padding:4px 8px;
  text-align:left;
  font-size:15px;
  width:50%;


}

</style>
</head>
<body>
  <div class= "rectangle1">
    <h1 class="center" style="color:black;" style="font-size:25px;">
      PET Department
     </h1>
     <h2 class="center" style="color:black;" style="font-size:22px;">
       Pain point & solution  analysis
      </h2>
  </div>
  <table>
    <tr>
      <th class="tableth" style="color:white;" >Pain Points</th>
      <th class="tableth" style="color:white;">Solutions</th>
    </tr>
    <tr>
      <td class="tabletd" style= "background-color: #FED8B1" rowspan="2">It is still challenging to rule out all other possible causes before diagnosing AD, making new imaging technologies a necessity.
</td>
      <td class="tabletd" style= "background-color: #FED8B1"><b>Biograph mMR/Biograph mCT:</b>  The acquisition of MRI or CT imaging combined with PET data allows  a precise visualization of areas of decreased glucose metabolism, helping to differentiate AD from other forms of dementia. It also enables shorter acquisition times and optimizes accuracy with motion compensation in agitated patients.
</td>
</tr>
<tr>
<td class="tabletd" style= "background-color: #FED8B1"><b>syngo.via.PET Amyloid Plaque software: </b> This software uses dedicated neurological quantification algorithms that helps to identify pathologies of the brain by comparing AD patient exams against a population database of normal, healthy brains and comparing exams over time.
</td>
</tr>
<tr>
  <td class="tabletd" style= "background-color: #FED8B1"> As symptoms can vary greatly in Alzheimer's patients, so does the extend of the different Alzheimer’s pathologies. Especially for testing novel drugs, it is therefor key to select target clinical trial participants.
</td>
<td class="tabletd" style= "background-color: #FED8B1"> <b>Image-based therapy personalization : </b>Already the first signs of neuropathological changes can be detected via in vivo accumulation of radioactive imaging agent for specific targets – or biomarkers –  under a PET camera. This refines the diagnostic process and clinicians can select the suitable patient population that may benefit from investigational drugs being tested.
</td>
</tr>
